Aligos Therapeutics presents data from ALG-000184 at EASL

Aligos Therapeutics announced data from six poster presentations at the European Association for the Study of the Liver, or EASL, Congress 2024, being held June 5-8 in Milan, Italy. The clinical poster presentations highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B, or CHB, in both HBeAg-positive and HBeAg-negative subjects. Data from 72 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression in 9/10 HBeAg-positive CHB subjects with no viral breakthrough. New data also showed that as HBeAg declined to near negativity in this patient population, anti-HBe antibody levels exhibited a positive trend. Reported for the first time were antiviral and safety data in HBeAg-negative CHB subjects who received a daily single dose of 300 mg ALG-000184 monotherapy for 60 weeks. In all 11 subjects, complete suppression of HBV DNA and RNA were noted, with reduction in HBcrAg levels indicating inhibition of HBV replication, as well as inhibition of cccDNA establishment/replenishment. In both patient populations, ALG-000184 continues to be well tolerated with no viral breakthrough. Additionally, other preclinical poster presentations demonstrate the potential of next generation siRNAs for treating metabolic dysfunction-associated steatohepatitis, or MASH, and CHB as well as a novel CAM-A molecule for the treatment of CHB.